Skip to main content

Table 3 Comparison of adverse events by the best objective response on target lesions

From: The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective study

Adverse events

All grades (%)

Grades 3/4 (%)

All cases (n = 50)

CR/PR (n = 12)

SD (n = 22)

PD (n = 6)

NE (n = 10)

All cases (n = 50)

CR/PR (n = 12)

SD (n = 22)

PD (n = 6)

NE (n = 10)

Any

100

100

100

100

100

30

25

27

50

30

Hematologic

Anemia

58

58

54

67

60

4

0

0

17

10

Neutorophils decreased

44

50

46

67

20

6

0

5

33

0

Lymphocyte decreased

36

42

36

50

20

6

8

5

0

10

Platelet decreased

58

67

50

83

50

24

17

27

50

10

Creatinine increased

38

33

41

33

40

0

–

–

–

–

Non-hematologic

Hypertension*

56

84

59

33

30

2

0

5

0

0

Hypothyroidism*

46

42

59

33

30

0

–

–

–

–

Fatigue

36

33

32

50

40

0

–

–

–

–

Diarrhea

30

33

36

0

30

0

–

–

–

–

Mucositis oral

28

17

46

17

10

0

–

–

–

–

Hand-foot syndrome

20

25

27

17

0

0

–

–

–

–

Fever up

18

25

9

33

20

0

–

–

–

–

Hemorrhage

16

8

23

17

10

0

–

–

–

–

Heart failure

4

8

5

0

0

0

–

–

–

–

  1. All the statistical analysis is performed with Fisher’s exact test, * P < 0.05
  2. CR complete response; PR pertial response; SD stable disease; PD progressive disease; NE not evaluable
Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us